Precision medicine for metastatic prostate cancer via estrogen and androgen signal

Research Project

Project/Area Number	18K09128
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56030:Urology-related
Research Institution	Jichi Medical University
Principal Investigator	Fujimura Tetsuya 自治医科大学, 医学部, 教授 (50376448)
Co-Investigator(Kenkyū-buntansha)	高山賢一地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 専門副部長 (50508075)
Project Period (FY)	2018-04-01 – 2021-03-31
Project Status	Completed (Fiscal Year 2020)
Budget Amount *help	¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000) Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywords	前立腺癌 / プレシジョンメディシン / アンドロゲン / エストロゲン / 分子診断 / TRIM36
Outline of Final Research Achievements	Androgen deprivation therapy (ADT) for prostate cancer aims to control the action of androgen receptors (ARs) involved in the growth of cancer cells. In some cases, long-term survival is achieved with this ADT, and in other cases, castration resistant prostate cancer (CRPC) develops relatively early, leading to cancer death. This study created a nomogram that predicts cancer-specific survival of metastatic prostate cancer cases using paraffin specimens of prostate needle biopsy by a simple method, and is expected to develop into precision medicine.
Academic Significance and Societal Importance of the Research Achievements	本研究にて診断時のパラフィン標本から比較的簡易にADTの耐久性を診断することができた。ADTの治療効果が低い症例は初期にタキサン系抗癌剤、免疫チェックポイント阻害薬や新規の治療薬の候補となりえる。今後は独立したコホートでの検証や、商用化に向けた妥当性の検討が必要である。